Next Article in Journal
Nurse Navigators’ Views on Patient and System Factors Associated with Navigation Needs among Women with Breast Cancer
Previous Article in Journal
Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
Article

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC

1
Department of Medicine, Medical University of Vienna, 1090 Vienna, Austria
2
Innere Medizin–Onkologie und Hämatologie, Klinikum Oldenburg, 26133 Oldenburg, Germany
3
Department of Clinical Oncology, Instituto Alexander Fleming, Buenos Aires C1426ANZ, Argentina
4
Department of Medical Oncology, University Hospital Marqués de Valdecilla, IDIVAL, 39008 Santander, Spain
5
Department of Medical Oncology, Policlinico Universitario Campus Bio-Medico Rome, 00128 Rome, Italy
6
Department of Cancer Medicine, Hammersmith Hospital, London SW7 2AZ, UK
7
Department of Hepato-Gastroenterology, University Hospital of Saint-Étienne, 42270 Saint-Étienne-Priest-en-Jarez, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(3), 2097-2106; https://doi.org/10.3390/curroncol28030194
Received: 20 May 2021 / Accepted: 27 May 2021 / Published: 4 June 2021
(This article belongs to the Section Gastrointestinal Oncology)
The SCOPE project aimed to better understand practice patterns, identify drivers for treatment goals, and determine third- and fourth-line treatment choices for patients with metastatic colorectal cancer (mCRC). The survey was developed by an expert panel of gastrointestinal oncologists. Questions concerned general practice patterns, and treatment decisions for three hypothetical patient case scenarios. Participants had to routinely manage patients with mCRC. We present results from 629 participants who provided input on patient treatment scenarios (data cutoff: 17/01/2020). Prolonging overall survival (OS; 51%) was the main aim in first line. In third line, quality of life (QOL) was the primary goal (34%). Forty-three percent also cited efficacy-focused goals; 18% and 13% noted prolonging OS and improving progression-free survival as main aims, respectively. For fit and active patients, 89% of respondents considered trifluridine-tipiracil an appropriate third-line treatment; regorafenib (31%) or clinical trial enrollment (29%) were the fourth-line options. For patients with comorbidities and limited caregiver support, trifluridine-tipiracil was the preferred third-line treatment (70%). For KRAS-mutated patients with comorbidities and adverse events who received prior oxaliplatin, 90% considered oxaliplatin rechallenge an unsuitable third-line treatment, mainly due to the risk of cumulative toxicity (75%). In the third/fourth-line settings, trifluridine-tipiracil followed by regorafenib was the most common option (54%); 17% chose regorafenib followed by trifluridine-tipiracil. Efficacy coupled with QOL are important goals in third-line treatment. Daily practice patterns reflect the guideline recommendations in third- and fourth-line settings, with a trend toward using trifluridine-tipiracil versus regorafenib in KRAS-wildtype and KRAS-mutant tumors. View Full-Text
Keywords: metastatic colorectal cancer; practice patterns; trifluridine-tipiracil; regorafenib; KRAS-mutated mCRC; KRAS-wildtype mCRC metastatic colorectal cancer; practice patterns; trifluridine-tipiracil; regorafenib; KRAS-mutated mCRC; KRAS-wildtype mCRC
Show Figures

Figure 1

MDPI and ACS Style

Prager, G.; Köhne, C.-H.; O’Connor, J.M.; Rivera, F.; Santini, D.; Wasan, H.; Phelip, J.M. The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC. Curr. Oncol. 2021, 28, 2097-2106. https://doi.org/10.3390/curroncol28030194

AMA Style

Prager G, Köhne C-H, O’Connor JM, Rivera F, Santini D, Wasan H, Phelip JM. The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC. Current Oncology. 2021; 28(3):2097-2106. https://doi.org/10.3390/curroncol28030194

Chicago/Turabian Style

Prager, Gerald; Köhne, Claus-Henning; O’Connor, Juan M.; Rivera, Fernando; Santini, Daniele; Wasan, Harpreet; Phelip, Jean M. 2021. "The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC" Curr. Oncol. 28, no. 3: 2097-2106. https://doi.org/10.3390/curroncol28030194

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop